或不:对性结肠炎的"治疗目标"进行批评
Klaus R Herrlinger1, Eduard F Stange2
1Internal Medicine I, Asklepios Klinik, Hamburg, Germany.
Expert review of gastroenterology & hepatology
|August 28, 2024
概括
对于性结肠炎 (UC) 的STRIDE共识引入了内镜目标,但本次审查批评了它们的可实现性和证据. 目前的UC治疗策略应该优先考虑患者的福祉,而不是未经证实的UC治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病是什么
- 性结肠炎研究研究
背景情况:
- STRIDE共识建议将内镜治疗作为性结肠炎 (UC) 管理中的治疗目标.
- 目前的UC治疗指南通常依赖于临床终点,如MAYO得分,定义各不相同.
研究的目的:
- 批判性地评估STRIDE共识,重点关注其拟议的内镜目标的局限性和可实现性.
- 评估现有证据,支持UC中的"治疗以准"策略.
主要方法:
- 进行了关于性结肠炎相关文献的叙述性综述.
- 通过PubMed搜索,使用关键词"性结肠炎"来识别出版物.
主要成果:
- 目前在UC的内镜目标对于大多数患者来说是具有挑战性的.
- 根据这些目标,支持升级UC治疗的好处的证据有限.
- 在UC内,内镜缓解的定义各不相同,影响一致性.
结论:
- 由于STRIDE共识依赖于严格的内镜目标,因此需要进一步验证.
- 临床医生应谨慎对待UC的"治疗目标",直到证明优于标准护理.
- 在当前的UC治疗范式中,专注于临床福祉仍然是最重要的.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


